Osmotica Pharmaceuticals plc (OSMT)
$1.87
$0.01
(0.54%)
As on 22-Mar-2022 09:30EDT
Market cap
$92 Mln
Revenue (TTM)
$-- Mln
P/E Ratio
--
P/B Ratio
1.6
Div. Yield
0 %
Quality Score
/10
Growth Score
/10
Valuation Score
/10
Momentum Score
/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-- Mln
-
ROE
-1 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0
-
Debt to Equity
2.3
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
83,289,800
5 Years Aggregate
CFO
$101.76 Mln
EBITDA
$-306.40 Mln
Net Profit
$-546.86 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Osmotica Pharmaceuticals plc (OSMT)
| 73.1 | 25.5 | 74.8 | -51.7 | -33.5 | -- | -- |
|
BSE Sensex*
| -9.6 | -2.7 | 2.9 | -5.0 | 5.4 | 5.7 | 10.4 |
|
Company
|
2021
|
2020
|
2019
|
|---|---|---|---|
|
Osmotica Pharmaceuticals plc (OSMT)
| -73.8 | -41.1 | -9.8 |
|
BSE Sensex
| 22.0 | 15.8 | 14.4 |
|
BSE Sensex
| 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Osmotica Pharmaceuticals plc (OSMT)
Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products in the United States, Argentina, and Hungary. The company's promoted products include M-72, a... methylphenidate hydrochloride extended-release tablet to treat attention deficit hyperactivity disorder (ADHD); Osmolex ER, an amantadine extended-release tablet for the treatment of Parkinson's disease and drug-induced extrapyramidal reactions in adults; Arbaclofen extended-release tablets which is in phase III clinical trial for the treatment of multiple sclerosis spasticity; Upneeq, an oxymetazoline hydrochloride ophthalmic solution for the treatment of Blepharoptosis; and OS870 which is in Phase I clinical trial for the treatment of neurodegenerative disorders. It also provides women's health products, including Divigel for menopause; and OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods. In addition, the company's non-promoted products comprise methylphenidate ER tablets for ADHD; venlafaxine ER tablets to treat major depressive disorders and social anxiety disorders; hydromorphone ER for treating pain; nifedipine ER for hypertension; sodium benzoate/sodium phenylacetate for the treatment of hyperammonemia; oxybutynin ER for overactive bladder; prescription prenatal vitamins for treating nutritional requirements during pregnancy; Lorzone, an immediate-release form of chlorzoxazone indicated for the treatment of acute musculoskeletal pain in conjunction with rest and physical therapy; ConZip, a tramadol hydrochloride for the management of pain; and nitrofurantoin for the treatment of urinary tract infections, as well as Osmodex and other abbreviated new drug applications. Osmotica Pharmaceuticals plc is headquartered in Bridgewater, New Jersey. Read more
-
Chairman, Pres & CEO
Mr. Brian A. Markison
-
Chairman, Pres & CEO
Mr. Brian A. Markison
-
Headquarters
Bridgewater, NJ
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Osmotica Pharmaceuticals plc (OSMT)
What is the current share price of Osmotica Pharmaceuticals plc (OSMT) Today?
The share price of Osmotica Pharmaceuticals plc (OSMT) is $1.87 (NASDAQ) as of 22-Mar-2022 09:30 EDT. Osmotica Pharmaceuticals plc (OSMT) has given a return of -33.54% in the last 3 years.
What is the current PB & PE ratio of Osmotica Pharmaceuticals plc (OSMT)?
Since, TTM earnings of Osmotica Pharmaceuticals plc (OSMT) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2020 |
-- |
-- |
2019 |
-- |
-- |
2018 |
-- |
-- |
2017 |
-- |
-- |
2016 |
-- |
-- |
What is the 52 Week High and Low of Osmotica Pharmaceuticals plc (OSMT)?
The 52-week high and low of Osmotica Pharmaceuticals plc (OSMT) are Rs -- and Rs -- as of 06-Sep-2026.
What is the market cap of Osmotica Pharmaceuticals plc (OSMT)?
Osmotica Pharmaceuticals plc (OSMT) has a market capitalisation of $ 92 Mln as on 22-Mar-2022. As per SEBI classification, it is a company.
Should I invest in Osmotica Pharmaceuticals plc (OSMT)?
Before investing in Osmotica Pharmaceuticals plc (OSMT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.